Literature DB >> 8510073

Solubilization and characterization of the A2-adenosine receptor.

C Nanoff1, G L Stiles.   

Abstract

Binding of [3H]CGS 21680, an agonist radioligand selective for A2-adenosine receptors (A2AR), to membranes and solubilized preparations from bovine brain striatum revealed labelling of a single high affinity binding state. In membranes, guanine nucleotides per se were ineffective in modulating agonist binding whereas cations, Na+ and Mg++, had distinct effects. The addition of NaCl (200 mM) as well as the Mg(++)-free preparation of membranes led to a significant decrease in binding affinity and the number of binding sites. Moreover, the presence of Na+ was required for the demonstration of a guanine nucleotide effect, i.e. a decrease in maximal binding. Following solubilization, agonist-A2AR interactions were sensitive to guanine nucleotides even in the absence of Na+; guanine nucleotides and Na+ had additive effects in reducing the number of binding sites. Moreover, the effect of GTP was reversible, i.e. binding returned to control levels upon removal of the nucleotide. This suggests the A2AR and its G protein (presumably Gs) are solubilized as a functional unit and may not dissociate even in the presence of GTP following solubilization. We, therefore, believe that a "tight" association exists between receptor and G protein (Gs), and that guanine nucleotides and sodium act at different sites on the R-G complex. Drawing an analogy with similar observations on the avian beta-adrenergic receptor (Hertel et al, J. Biol. Chem. 265:17988-94, 1990; Parker & Ross, J. Biol. Chem. 266:9987-96, 1991) we postulate that the regulatory features of the A2AR can be attributed to a distinct receptor domain that interacts with cellular regulatory elements.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510073     DOI: 10.3109/10799899309073703

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  8 in total

1.  Dominance of G(s) in doubly G(s)/G(i)-coupled chimaeric A(1)/A(2A) adenosine receptors in HEK-293 cells.

Authors:  A L Tucker; L G Jia; D Holeton; A J Taylor; J Linden
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

Review 2.  The A(2A)-adenosine receptor: a GPCR with unique features?

Authors:  J Zezula; M Freissmuth
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

3.  Constitutive activity of the A2A adenosine receptor and compartmentalised cyclic AMP signalling fine-tune noradrenaline release.

Authors:  Edin Ibrisimovic; Helmut Drobny; Qiong Yang; Thomas Höfer; Stefan Boehm; Christian Nanoff; Klaus Schicker
Journal:  Purinergic Signal       Date:  2012-04-05       Impact factor: 3.765

4.  Desensitization of the canine A2a adenosine receptor: delineation of multiple processes.

Authors:  T M Palmer; T W Gettys; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

5.  Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils.

Authors:  Katia Varani; Stefania Gessi; Stefania Merighi; Valeria Iannotta; Elena Cattabriga; Susanna Spisani; Ruggero Cadossi; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

6.  125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor.

Authors:  T M Palmer; S M Poucher; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1995-12       Impact factor: 4.436

7.  Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding.

Authors:  X D Ji; K A Jacobson
Journal:  Arch Biochem Biophys       Date:  1993-09       Impact factor: 4.013

8.  Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.

Authors:  C Zocchi; E Ongini; S Ferrara; P G Baraldi; S Dionisotti
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.